Table 2 Correlation between primary recurrence site and clinicopathological features in HR+/HER2− breast cancer not received chemotherapy
Parameters | Primary recurrence site (n = 42) | |||||
|---|---|---|---|---|---|---|
Local recurrence (n = 18) | Not local recurrence (n = 24) | p value | Locoregional recurrence (n = 31) | Distant metastasis (n = 11) | p value | |
Age at operation (years old) | ||||||
 ≤ 60 | 11 (61.1%) | 14 (58.3%) | 0.856 | 17 (54.8%) | 8 (72.7%) | 0.299 |
14 (45.2%) | 3 (27.3%) | |||||
 > 60 | 7 (38.9%) | 10 (41.7%) | ||||
Tumor size (mm) | ||||||
 ≤ 20.0 | 9 (50.0%) | 12 (50.0%) | 1.000 | 5 (48.4%) | 6 (54.5%) | 0.726 |
 > 20.0 | 9 (50.0%) | 12 (50.0%) | 16 (51.6%) | 5 (45.5%) | ||
Tumor size (mm) | ||||||
 ≤ 30.0 | 15 (83.3%) | 19 (79.2%) | 0.734 | 24 (77.4%) | 10 (90.9%) | 0.328 |
 > 30.0 | 3 (16.7%) | 5 (20.8%) | 7 (22.6%) | 1 (9.1%) | ||
Pathological lymph node metastasis | ||||||
pN0, pN1mi | 18 (100.0%) | 17 (70.8%) | 0.012 | 29 (93.5%) | 6 (54.5%) | 0.003 |
pN1a | 0 (0.0%) | 7 (29.2%) | 2 (6.5%) | 5 (45.5%) | ||
Progesterone receptor | ||||||
Negative | 2 (11.1%) | 1 (4.2%) | 0.387 | 3 (9.7%) | 0 (0.0%) | 0.284 |
Positive | 16 (88.9%) | 23 (95.8%) | 28 (90.3%) | 11 (100.0%) | ||
Ki67 | ||||||
 ≤ 20% | 16 (88.9%) | 19 (79.2%) | 0.403 | 26 (83.9%) | 9 (81.8%) | 0.875 |
 > 20% | 2 (11.1%) | 5 (20.8%) | 5 (16.1%) | 2 (18.2%) | ||
Surgical treatment | ||||||
BCT and radiation therapy | 7 (38.9%) | 11 (45.8%) | 0.653 | 0 (32.3%) | 8 (72.7%) | 0.020 |
Mastectomy | 11 (61.1%) | 13 (54.2%) | 21 (67.7%) | 3 (27.3%) | ||
Lymphatic invasion | ||||||
ly0 | 10 (55.6%) | 11 (45.8%) | 0.533 | 16 (51.6%) | 5 (45.5%) | 0.726 |
ly1 | 8 (44.4%) | 13 (54.2%) | 15 (48.4%) | 6 (54.5%) | ||
Venous invasion | ||||||
v0 | 17 (94.4%) | 22 (91.7%) | 0.729 | 29 (93.5%) | 10 (90.9%) | 0.770 |
v1 | 1 (5.6%) | 2 (8.3%) | 2 (6.5%) | 1 (9.1%) | ||
Nuclear grade | ||||||
1, 2 | 15 (83.3%) | 21 (87.5%) | 0.703 | 26 (83.9%) | 10 (90.9%) | 0.567 |
3 | 3 (16.7%) | 3 (12.5%) | 5 (16.1%) | 1 (9.1%) | ||
Adjuvant endocrine therapy | ||||||
TAM (+ LH-RH agonist) | 8 (44.4%) | 9 (37.5%) | 0.650 | 13 (41.9%) | 4 (36.4%) | 0.746 |
ANA | 10 (55.6%) | 15 (62.5%) | 18 (58.1%) | 7 (63.6%) | ||
Disease free survival (days) | ||||||
 ≤ 1462 | 12 (66.7%) | 9 (37.5%) | 0.061 | 19 (61.3%) | 2 (18.2%) | 0.014 |
 > 1462 | 6 (33.3%) | 15 (62.5%) | 12 (38.7%) | 9 (81.8%) | ||
TILs density | ||||||
 ≤ 10 | 15 (83.3%) | 21 (87.5%) | 0.703 | 27 (87.1%) | 9 (81.8%) | 0.667 |
 > 10 | 3 (16.7%) | 3 (12.5%) | 4 (12.9%) | 2 (18.2%) | ||
TILs density | ||||||
Absent | 0 (0.0%) | 6 (25.0%) | 0.022 | 2 (6.5%) | 4 (36.4%) | 0.015 |
Not absent | 18 (100.0%) | 18 (75.0%) | 29 (93.5%) | 7 (63.6%) | ||